ArticleBMC nephrology2025

Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study.

Zhiliang Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.